AstraZeneca, a British pharmaceutical company, is in the final stage of the COVID-19 vaccine development. The potential vaccine has not entered serial production yet. However, numerous countries are getting in line making agreements to be armed with a real weapon against the deadly virus.

Interestingly, the UK and the US authorities, Serum Institute of India, and several European countries, including Italy, France, Germany, and the Netherlands, are among the company’s clients. The total number of vaccines ordered is 2 billion doses. AstraZeneca’s manufacturing capacity allows the company to work with such volumes. Based on the arranged settlement, deliveries of the new vaccine will start by the end of this year. In addition, the company is committed to accelerating access to the vaccine in other countries that wish to participate in the initiative. Therefore, AstraZeneca intends to collaborate with other pharmaceutical companies in order to expand  manufacturing capacity further.

According to the contract signed between AstraZeneca and Inclusive Vaccines Alliance (IVA), in case of successful trials, the company should provide Europe with up to 400 million doses of vaccine.